Glioblastoma is the most frequent brain tumor and is invariably lethal. Current standard treatment for newly diagnosed patients consists of surgery, radiotherapy and temozolomide. Cancer stem cells that are resistant to chemo- and radiotherapy are thought to drive r egrowth of the cancer in a more aggressive form.
The present invention is a Dendritic cell based vaccine against patient-derived glioblastoma cancer cells with stem cell like properties. Phase I/II study is completed and show improvement in progression-free survival (PFS) from 8 to 20 months relative to historical data. Preliminary data from compassionate use treatment of 4 patients with 2 nd gen. DC protocol indicate stronger immune response and potentially improved therapeutic response.
Have orphan drug designation in Europe.